What is ILUVIEN used for?
Indication: ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg is indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.
How does ILUVIEN?
Q How does ILUVIEN work? A When DME develops, fluid collects in a part of the eye called the macula causing it to swell, which results in blurry vision. ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg is a corticosteroid used in the treatment of DME.
How much does ILUVIEN cost?
Table 5CADTH Cost Comparison Table of Treatments for Adults with Diabetic Macular Edema
| Comparator | Strength | Price ($) |
|---|---|---|
| Fluocinolone acetonide (Iluvien) | 0.19 mg | 7,770.0000a |
| Glucocorticoid Receptor Agonist for the Treatment of Retinal Conditions | ||
| Dexamethasone implant (Ozurdex) | 700 mcg (single use) | 1,295.0000b |
When was ILUVIEN approved?
On September 26, 2014, The US Food and Drug Administration approved ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular …
Is ILUVIEN a steroid?
The medicine in ILUVIEN is called fluocinolone acetonide (FAc), a type of steroid called a corticosteroid. FAc helps treat the inflammation associated with diabetic macular edema (DME).
What is injection ozurdex used for?
Ozurdex (dexamethasone) Intravitreal Implant is a steroid injected into the eye to treat swelling that may occur when there is a blockage of certain blood vessels in your eyes. Ozurdex is also used to treat non-infectious uveitis affecting the posterior (rear) segment of the eye.
How much does iluvien cost?
Is iluvien FDA approved?
When was iluvien approved?
How successful is Ozurdex?
Repeated treatment with Ozurdex at a six-month interval has been shown to be safe and effective in patients with ME related to RVO. Although cataract progression has been noted upon repeated injection, cataract extraction has remained rare in clinical studies of up to one year in duration.
How often is Ozurdex given?
Conclusion: Repeated intravitreal Ozurdex on an ‘as-needed’ basis, with a retreatment interval <6 months, may produce long-term clinically meaningful benefits in the treatment of ME due to RVO, without other significant side effects than expected after intraocular corticosteroid treatment.